Standard BioTools Inc
NASDAQ:LAB

  • LAST PRICE
    2.5550
  • TODAY'S CHANGE (%)
    0.0550 (2.2000%)
  • Bid / Lots
    2.5500/ 264
  • Ask / Lots
    2.5600/ 162
  • Open / Previous Close
    2.5100 / 2.5000
  • Day Range
    2.4850
    2.5900
  • 52 Week Range
    1.5700
    3.1600
  • Volume
    2,547,736

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • May 8, 2024

      Show headlines and story abstract

    • 4:07PM ET on Wednesday May 08, 2024 by MT Newswires
      Companies Mentioned: LAB
      04:07 PM EDT, 05/08/2024 (MT Newswires) -- ...

    • 4:01PM ET on Wednesday May 08, 2024 by GlobeNewswire
      Companies Mentioned: LAB

    • 4:01PM ET on Wednesday May 08, 2024 by Dow Jones
      Companies Mentioned: LAB

    • 4:01PM ET on Wednesday May 08, 2024 by Dow Jones
      Companies Mentioned: LAB
      -------------------------- --------------------------- March 31, March 31, March 31, March 31, 2024 2023 2024 2023 ------------ ------------ ------------- ------------ Operating expenses $ 84,370 $ 28,874 $ 75,760 $ 97,149 Restructuring and related charges (4,284) (1,150) (4,284) (1,150) Transaction and integration expenses (17,163) -- (14,733) (17,587) Stock-based compensation expense (11,372) (2,795) (5,276) (10,452) Amortization of acquired intangible assets (150) -- (150) (150) Depreciation and amortization (2,065) (539) (2,199) (1,878) Gain/loss on disposal of property and equipment (14) -- (14) (16) Non-GAAP operating expenses $ 49,322 $ 24,390 $ 49,105 $ 65,916 ======= ======= ======= === ======= R&D operating expenses $ 15,980 $ 6,429 $ 16,632 $ 20,573 Stock-based compensation expense (1,328) (416) (1,328) (2,192) Depreciation and amortization (871) (150) (884) (631) Non-GAAP R&D operating expenses $ 13,781 $ 5,863 $ 14,420 $ 17,750 ======= ======= ======= === ======= SG&A expenses $ 46,943 $ 21,295 $ 40,112 $ 57,689 Stock-based compensation expense (10,044) (2,379) (3,948) (8,261) Amortization of acquired intangible assets (150) -- (150) -- Depreciation and amortization (1,194) (389) (1,315) (1,247) Gain/loss on disposal of property and equipment (14) -- (14) (16) Non-GAAP SG&A expenses $ 35,541 $ 18,527 $ 34,685 $ 48,166 ======= ======= ======= === ======= STANDARD BIOTOOLS INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION (In thousands) (Unaudited) ITEMIZED RECONCILIATION OF GAAP NET LOSS TO NON-GAAP ADJUSTED EBITDA As Reported Non-GAAP Pro Forma Combined -------------------------- --------------------------- Three Months Ended Three Months Ended -------------------------- --------------------------- March 31, March 31, March 31, March 31, 2024 2023 2024 2023 ------------ ------------ ------------- ------------ Net loss $(32,157) $(16,843) $(50,019) $(45,053) Income tax expense 128 263 -- -- Interest income, net (5,174) (72) (5,253) (5,741) Amortization of acquired intangible assets 2,106 2,800 2,137 3,506 Depreciation and amortization 3,089 862 3,243 2,555 Bargain purchase gain (25,213) -- -- (25,213) Restructuring and related charges 4,284 1,150 4,284 1,150 Transaction and integration expenses 17,163 -- 14,733 17,587 Stock-based compensation expense 11,611 3,148 5,515 10,848 Cost of sales adjustment (1,812) -- -- (1,337) Gain/loss on disposal of property and equipment 14 -- 14 16 Other non-operating expense 2,234 59 2,234 -- Adjusted EBITDA $(23,728) $ (8,633) $(23,114) $(41,682) ======= ======= ======= =======

  • Apr 25, 2024

Peers Headlines